CBDNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Breakthrough Lipid-Based Delivery System Revolutionizes Delivery of Cannabinoids and More

Company: Lexaria Bioscience Corp. (LXRP)
Category: Stock Spotlights

Pioneering biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed a breakthrough lipid-based system that facilitates more efficient delivery of bioactive compounds—not only enhancing bio-absorption and bioavailability but also improving taste, smell and the onset of action. Lexaria intends to out-license this patented and proprietary technology, and the company has already applied this delivery technology to its line of products, which includes ViPova, Lexaria Energy and TurboCBD. An article further discussing this reads: “Lexaria’s novel technology, DehydraTECH™, ticks all these boxes by infusing the molecules of organically sourced hemp oil, high in cannabidiol (CBD), inside the molecules of lipids. Lipids seem a natural choice, since the human endocannabinoid system is itself lipid-based. Using them as a vehicle for delivering cannabinoids in curatives results in more absorption, less waste and, just as importantly, fewer side effects (http://cnw.fm/Vm2hR). With DehydraTECH, a little hemp oil goes a long way, improving the healthful benefits and, of course, saving money.”

To view the full article, visit http://cnw.fm/wX3cV

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information about Lexaria, visit www.lexariabioscience.com.

More from CannabisNewsBreaks

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
[email protected]

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000